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differentiation or simply taking the middle
way, these results offer new insight into
CD4+ T cell differentiation.
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The biology of interleukin-17C (IL-17C) has remained largely a mystery for more than a decade. Chang et al.
(2011), in this issue of Immunity, and two other reports (Song et al., 2011; Ramirez-Carrozzi et al., 2011)
demonstrate that IL-17C has broad functions in a variety of tissues.Of the six members of the IL-17 cytokine
family, three have been shown to play
prominent roles in both innate and adap-
tive immune responses, including the
founding member IL-17A, its closest
sequence homolog IL-17F, and IL-17E
(IL-25). For the remaining three family
members (IL-17B, IL-17C, and IL-17D),
very little is known regarding their tissue
expression pattern and biological func-
tion (Gaffen, 2009). IL-17C was cloned
by Li et al. (2000), who showed that it stim-
ulated THP-1 cells (a human monocytic
cell line), to produce inflammatory cyto-
kines TNFa and IL-1b. A handful of subse-
quent studies by several other groups
then showed a recurring pattern that
IL-17C was not expressed under nor-
mal conditions but was upregulated and
played significant roles in inflamed tissues
including the joint, lung, and skin (Yama-
guchi et al., 2007; Wu et al., 2007; Johan-
sen et al., 2009). Despite these advances,
IL-17C remained an orphan cytokine.
It was hitherto unclear what receptor
IL-17C engages, which cell types express
the cognate receptor, and what signaltransduction pathway mediates its func-
tion. This month, three new papers shed
light on these intriguing questions, and
the answers span both innate and adap-
tive immune responses—similar to other
IL-17 family members—in target organs
as diverse as the central nervous system
and tissues with barrier functions. Thus,
another member of the IL-17 family is
indispensable for type 17 immunity, with
its own unique signature pathway biology.
In this issue of Immunity, Chang et al.
(2011) began their study by noting that
IL-17C mRNA expression was upre-
gulated 15-fold in the central nervous
system (CNS) of mice with experimen-
tal autoimmune encephalomyelitis (EAE)
compared with naive control mice. Then
they discovered that Il17c/ mice ex-
hibited a striking reduction both in the
severity and incidence of EAE, an im-
portant observation. This phenotype was
supported at the cellular level by reduced
numbers in the CNS of total CD4+ T cells
and IL-17+, IFNg+, and double-producer
cells and at themolecular level by reduced
mRNA expression of IL-17A, IFN-g, andCCL20. These results suggested that the
lack of accumulation of pathogenic CD4+
T cells in the Il17c/ mice was the key
factor in protection from disease. The
authors conclude that the initial CD4+ Th
cell differentiation and effector genera-
tion in secondary lymphoid tissues appear
to be intact in the Il17c/ mice and that
the defects in function do not appear until
either migration or accumulation in the
CNS occurs.
The authors then generated a series of
transfectant cell lines with IL-17 receptor
family members (IL-17RA to IL-17RE),
and made a second important observa-
tion: that IL-17C-Ig fusion protein specifi-
cally and uniquely bound IL-17RE. IL-17C
most likely binds to a heterodimer of
IL-17RA and IL-17RE on the basis of
two pieces of evidence: epitope-tagged
IL-17RE brought down IL-17RA in a
co-IP assay, and Il17ra/ transfectants
of Il17re lost their responsiveness to
IL-17C treatment in vitro. IL-17RE mRNA
was upregulated in in vitro generated
Th17 cells, but not in naive, natural or


















Figure 1. IL-17C Acts as an Autocrine Factor on Epithelial Cells and a Paracrine Factor on
Th17 Cells
IL-17C has been an orphan member of the IL-17 family of cytokines. Three recent studies showed
that IL-17C engages an IL-17RA and IL-17RE hetrodimeric receptor and signals via Act1 and IkB (not
shown). IL-17C is unique among the IL-17 family because it is produced mainly by epithelial cells rather
than hematopoietic cells. Th17 cells can express IL-17RE after activation in the presence of IL-1b and
IL-23. Engagement of IL-17C with the IL-17RA and IL-17RE hetrodimeric receptor serves as an amplifica-
tion signal to enhance inflammatory function of Th17 cells by upregulation of IL-17A. IL-17C production is
also induced in epithelial cells after exposure to PAMPs and inflammatory cytokines including IL-1b and
TNF-a. Because IL-17RA and IL-17RE are constitutively expressed on epithelial cells, IL-17C acts as an
autocrine factor to enable epithelial cells to produce Reg3g, S100A89, and S100A8 antimicrobial peptides.
However, epithelial cells still require lymphoid cell-derived IL-22 to fully activate their innate immune
functions. Thus, IL-17C biology spans both innate and adaptive immune responses.
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and TGF-b, further increased with IL-1
and IL-23 stimulation, andwas dependent
on Stat3, RORc and RORa transcription
factors. These data support the notion
that the heterodimer IL-17RA-IL-17RE is
the cognate receptor for IL-17C, which is
expressed on Th17 cells in vivo. Indeed,
in two additional independent studies,
Song et al. (2011) and Ramirez-Carrozzi
et al. (2011) also showed that IL-17C
engages IL-17RA-IL-17RE, thus firmly
establishing this complex as the receptor
for the previously orphaned ligand.
The third observation made by Chang
et al. (2011) was the function of IL-17C in
T cells and the signal transduction path-
ways mediating its effects. IL-17C stimu-
lation of IL-17RE-overexpressing Th17
cells resulted in an increase in IL-17A,
IL-17F, and IL-22 mRNA and protein ex-
pression (Figure 1), but had no effects on
IFNg production by Th1 cells. IL-17RE
engagement of IL-17C transduced sig-
nals though Act1 and IkB, both of which
have been shown in other studies to
be critical for EAE pathogenesis (Oka-
moto et al., 2010; Qian et al., 2007). To-
gether these results demonstrated that
IL-17C can bind IL-17RE to mediate aunique signaling pathway, and that it
plays an important role in regulating
adaptive T cell responses in a model of
autoimmunity.
Interestingly, the IL-17C fusion protein
can bindCD4+ T cells aswell as other sub-
set(s) of cells in mice with EAE. This
suggests that IL-17C could potentially
have effects on both adaptive immune
function as well as other tissues. Indeed,
in separate studies, Song et al. (2011)
andRamirez-Carrozzi et al. (2011) demon-
strated that IL-17C is predominantly
produced by epithelial cells and acts as
an autocrine factor on the same cells
(Figure 1). They showed that Toll-like
receptor (TLR) ligands, including flagellin
and LPS, induced IL-17C expression in
keratinocytes and intestinal epithelial cells
but not hematopoietic cells. This epithelial
cell specificity was confirmed with bone
marrow chimeras and Rag2/: Il2rg/
mice. In addition, treatment of mice
with a topical TLR7-TLR8 agonist, imiqui-
mod, promoted keratinocyte production
of IL-17C and induced psoriasis-like
lesions. To further delineate the signals
required, the authors used Myd88-defi-
cient mice to show that TNF-a can induce
IL-17C production independent of TLRImmunity 35signaling pathways. Thus, IL-17C is an
epithelial cell-derived factor triggered by
a variety of danger signals, including path-
ogen-associated molecular patterns, and
inflammatory cytokines IL-1b and TNF-a.
This innate source of IL-17C is unique,
given that other members of the IL-17
family, e.g., IL-17A and IL-17F, are mainly
produced by activated lymphoid cells.
One of the more surprising findings
from these latter studieswas that skin ker-
atinocytes and gut epithelial cells con-
stitutively expressed IL-17RE and can
respond to IL-17C (Figure 1). Oral infec-
tion with C. rodentium strongly promoted
IL-17C production, and both IL-17C and
IL-17RE expression were absolutely re-
quired for host survival. This is unex-
pected because it is thought that IL-23
induction of IL-22 production by lym-
phoid cells is necessary and sufficient
for host defense against C. rodentium
(Zheng et al., 2007). Previous studies
have showed that IL-22 acts as a para-
crine factor on epithelial cells and is es-
sential for induction of Reg3g, S100A89,
and S100A8 antimicrobial peptides. It is
remarkable that even though ‘‘normal’’
amounts of lymphoid cell-derived IL-22
were present in the Il17re/ mice after
infection, the epithelial cells failed to pro-
duce defensins, resulting in a lethal infec-
tion. The insight provided by these latter
two studies is that in the absence of intes-
tinal epithelial cell-derived IL-17C, induc-
tion of anti-microbial peptides and other
host defense mechanisms are abrogated.
The synergy of autocrine IL-17C with
paracrine IL-22 to induce optimal anti-
microbial response is indeed an important
finding. The implication is that hematopoi-
etic cell-derived factors are not sufficient
to promote mucosal inflammation. Intes-
tinal epithelial cell recognition of danger
signals and subsequent production of
IL-17C are required to activate the poten-
tially damaging host defensemechanisms.
These three new studies represent
important advances to the field and high-
light additional important questions that
need to be addressed. Although it is clear
that skin and gut epithelial cells produce
IL-17C, the source of IL-17C in the CNS
is not known. If IL-17C is produced in the
CNS, the likely source could be nonhema-
topoietic in origin. Do CD4+-specific-
Il17re/ mice recapitulate the Il17c/
EAE phenotype? This would lend stronger
support for the idea that IL-17C, October 28, 2011 ª2011 Elsevier Inc. 499
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CD4+ T cells, as other cell types clearly
express IL-17RE in vivo. Are Th17 cells
influenced by IL-17C in the gut and skin
in a fashion similar to that seen in the
CNS? It would seem that there are
multiple opportunities for crosstalk
between innate and adaptive cells
through the IL-17C-IL-17RE system,
given the varied expression pattern of
both ligand and receptor.
In this sense, IL-17C biology is yet
another example of the checks and
balances of the immune system, in which
activation of a single pathway is often not
sufficient to initiate a potentially damaging
host defense response. Thus, the IL-17
family indeed plays key roles in both
the hematopoietic cell-based defense500 Immunity 35, October 28, 2011 ª2011 Elagainst nonself agents as well as the
innate capacity of epithelial cells to recog-
nize danger signals.
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